

# Drug Coverage Decision for B.C. PharmaCare

## About PharmaCare

B.C. PharmaCare is a government-funded drug plan. It helps British Columbians with the cost of eligible prescription drugs and specific medical supplies.

## Details of Drug Reviewed

<b>Drug</b>	<b>dupilumab</b>
Brand Name	Dupilumab™
Dosage Forms	300 mg/2 mL and 200 mg/1.14mL subcutaneous injection
Manufacturer	Sanofi-Aventis Canada Inc.
<b>Submission Type</b>	<b>New Indication</b>
Use Reviewed	Moderate to severe atopic dermatitis in patients aged 12 years and older
Common Drug Review (CDR)	Yes, CDR recommended: <b>to Reimburse with clinical criteria and/or conditions</b> . Visit the CDR website for more details: <a href="https://www.cadth.ca/sites/default/files/cdr/complete/SR0636%20Dupilumab%20-%20CDEC%20Final%20-%20Recommendation%20April%2024%2C%202020%20for%20posting.pdf">https://www.cadth.ca/sites/default/files/cdr/complete/SR0636%20Dupilumab%20-%20CDEC%20Final%20-%20Recommendation%20April%2024%2C%202020%20for%20posting.pdf</a>
Drug Benefit Council (DBC)	The DBC met on June 1, 2020, and considered various inputs including: clinical and pharmacoeconomic evidence review material and the recommendations from the Canadian Drug Expert Committee (CDEC). The DBC also considered Patient Input Questionnaire responses from 86 patients, 6 caregivers, and 2 patient groups, a CDR Patient Input Summary Clinical Practice Reviews from one specialist, and a Budget Impact Assessment.
<b>Drug Coverage Decision</b>	<b>Non-Benefit</b>
Date	May 11, 2021
Reasons	<b>Drug coverage decision is consistent with CDR recommendation.</b> <ul style="list-style-type: none"> <li>Clinical efficacy of dupilumab was assessed in randomized controlled trials (RCTs) that demonstrated improvements in atopic dermatitis severity, symptoms, and quality of life with dupilumab treatment compared with placebo. However, dupilumab has not been compared</li> </ul>

	<p>to any active comparator. There is a lack of data on efficacy and safety for the use of dupilumab in patients where topical prescription therapies are not advisable. Therefore, clinical value of dupilumab treatment and place in therapy is uncertain.</p> <ul style="list-style-type: none"> <li>• At the submitted price, dupilumab was not shown to be cost-effective relative to standard therapy for atopic dermatitis.</li> <li>• Based on the DBC recommendation, an attempt by the pan-Canadian Pricing Alliance was unsuccessful to address the concerns on cost and cost effectiveness.</li> </ul>
Other Information	None

### The Drug Review Process in B.C.

A manufacturer submits a request to the Ministry of Health (Ministry).

An independent group called the [Drug Benefit Council \(DBC\)](#) gives advice to the Ministry. The DBC looks at:

- whether the drug is safe and effective
- advice from a national group called the [Common Drug Review \(CDR\)](#)
- what the drug costs and whether it is a good value for the people of B.C.
- ethical considerations involved with covering or not covering the drug
- input from physicians, patients, caregivers, patient groups and drug submission sponsors

The Ministry makes PharmaCare coverage decisions by taking into account:

- the existing PharmaCare policies, programs and resources
- the evidence-informed advice of the DBC
- the drugs already covered by PharmaCare that are used to treat similar medical conditions
- the overall cost of covering the drug

Visit the [The Drug Review Process in B.C. - Overview](#) and [Ministry of Health - PharmaCare](#) for more information.

**This document is intended for information only.**

It does not take the place of advice from a physician or other qualified health care provider.